Arvinas Q3 2024 revenue $102.4M; cash $1.12B; VERITAC-2 data on track 4Q24/1Q25

ARVINAS, INC.

2024-Q3 EPS reported -$2.14 revenue$204,200,000

Q3 revenue $102.4M (vs $34.6M YoY) mainly from Novartis license $76.7M.
Cash and marketable securities $1.12B; sufficient to fund operations into 2027.
R&D $86.9M; G&A $75.8M incl. $43.4M lease termination loss.
VERITAC-2 Phase 3 topline data on track for 4Q24/1Q25; abemaciclib data at SABCS Dec 2024.
ARV-102 MAD portion started; KRAS G12D IND filing expected 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.